Canada markets closed

Immuron Limited (IMRN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.0450-0.0550 (-1.77%)
At close: 03:54PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close3.1000
Open3.0100
Bid3.0000 x 1000
Ask3.0800 x 800
Day's Range3.0000 - 3.0900
52 Week Range2.9950 - 9.2300
Volume10,509
Avg. Volume66,652
Market Cap17.716M
Beta (5Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-1.0400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    US DoD Uniformed Services University Travelers’ Diarrhea Clinical Update

    Key Points Manufacture of investigational medical products to support the Uniformed Services University (USU) clinical program to evaluate the efficacy of Travelan® and two other non-antibiotic OTC products in Travelers’ Diarrhea initiatedUSU are anticipating an enrolment start date of April 2022 and plan to enrol 1336 participants in total MELBOURNE, Australia, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developi

  • GlobeNewswire

    US DoD Naval Medical Research Center Clinical Update

    Key Points Manufacture of investigational medical products to support the US Naval Medical Research Centre (NMRC) clinical programs completed.IND submission to the U.S. Food and Drug administration (FDA) planned for Q1 CY2022 to support Two human phase II clinical trials.One trial will focus on the ability of the hyperimmune product to prevent infectious diarrhea caused by ETEC and scheduled to be initiated H1 CY2022.The second trial will focus on protecting volunteers against moderate to severe

  • GlobeNewswire

    IMM-124E – Demonstrates Antiviral T-Cell Immunity

    Key Points International Patent Filed Publication from the Hebrew University - Hadassah Medical Center Entitled: Augmented antiviral T cell immunity by oral administration of IMM-124E in preclinical models and a phase I/IIa clinical trial: A method for the prevention and treatment of COVID-19 MELBOURNE, Australia, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic pro